The modulatory actions of glutamate, the main excitatory neurotransmitter in the central nervous system (CNS), are exerted through the activation of metabotropic glutamate receptors (mGluRs). Of the eight known mGluRs (mGluR1-8), group III mGluRs (mGluR4, mGluR6, mGluR7, and mGluR8) are less understood because of the lack of selective ligands. Except for mGluR6, group III mGluRs are widely distributed throughout the CNS. They are mainly located on presynaptic terminals where they inhibit neurotransmitter release at glutamatergic and caminobutyric acid (GABA)ergic synapses. Their location at certain synapses is considered critical for normal CNS function, which makes them potential targets in neurological and psychiatric treatments. Novel ligands that are selective for group III mGluR subtypes have recently been developed. These compounds, which mainly target allosteric sites and act as positive or negative allosteric modulators (PAMs or NAMs) of glutamate transmission, are contributing to the understanding of the functional roles of group III mGluRs in a number of pathological conditions, such as epilepsy, anxiety, neurodegenerative diseases, and chronic pain. Moreover, the presence of group III mGluRs throughout the entire pain neuraxis and particularly in the descending system suggests that these endogenous substrates that extend from the cortex to the first spinal synapse are candidates for pain control. Recent data on chronic pain alleviation by group III mGluR ligands encourage further studies as pathological pain is one of the most troublesome diseases because of the current lack of satisfactory therapy. This review summarizes recent studies on group III mGluRs in animal models of chronic pain, which evidence an opposite modulation of mGluR7 and mGluR8 on pain responses and their capability to affect pain responses only in pathological states.
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N-terminal extracellular domain that contains a cysteine-rich domain and that detects and transmits binding-dependent conformation changes to the transmembrane domain and Venus flytrap domain. These domains are thought to be critical for glutamate binding, exogenous modulation by orthosteric agonists/antagonists, and constitutive receptor dimerization . The transmembrane domains contain binding sites for multiple allosteric modulators of mGluRs (Kunishima et al. 2000; Tsuchiya et al. 2002; Goudet et al. 2004; Muto et al. 2007) . The cytoplasmic C-terminal domain, which is the site of major splice variant expression, contains sites for intracellular protein binding and posttranslational modifications (Enz 2012) . Eight distinct mGluRs (mGluR1-8) have been cloned and characterized to date. They have been classified into three groups (I-III) based on their sequence homology, selective pharmacological activation/blockade, and transduction mechanisms. Group I mGluRs (mGluR1 and mGluR5) couple to the Gq protein, which activates phospholipase C, which in turn generates diacylglycerol and inositol 1,4,5-triphosphate and increases intracellular calcium and protein kinase C activity. The mGluRs of group II (mGluR2 and mGluR3) and group III (mGluR4, mGluR6, mGluR7, and mGluR8) couple to the Gi protein, which inhibits adenylyl cyclase, thus lowering the intracellular cAMP concentration and protein kinase A activation. mGluR3 is also coupled to guanylate cyclase inhibition (Wroblewska et al. 2006) . mGluRs and pain Group I mGluRs are widely expressed throughout the pain neuraxis. In particular, mGluR1 and mGluR5 in group I have been found on peripheral nociceptors (Bhave et al. 2001; Walker et al. 2001; Zhou et al. 2001; Hudson et al. 2002) and in the spinal cord (Valerio et al. 1997; Tang and Sim 1999) , periaqueductal gray (PAG) (Azkue et al. 1997) , thalamus (Lourenco et al. 2000) , amygdala (Neugebauer et al. 2003) , and prefrontal cortex (Sun and Neugebauer 2011) . The activation of group I mGluRs increases or decreases pain responses depending upon the activation site. The systemic administration of a group I mGluR antagonist, the (+/À)-2-amino-2-3-cis and trans-carboxycyclobutyl-3-(9-thioxanthyl) propionic acid, LY393053, showed significant analgesic effects in the mouse acetic acid writhing test . The administration of mGluR1 or mGluR5 agonists into rodent hind paws facilitates nociceptive responses (Bhave et al. 2001; Walker et al. 2001 ) and the development of inflammatory hyperalgesia (Walker et al. 2001; Palazzo et al. 2004) . At the dorsal root ganglia level, a subset of neurons expressing mGluR5 co-express the transient receptor potential vanilloid type 1 (TRPV1) (Walker et al. 2001; Zhou et al. 2001) , which is a pain transducer that is activated by physical (heat) and chemical substances (protons; lipid molecules, such as endovanilloids; lipoxygenase products; and natural products, such as capsaicin) (Caterina et al. 2000; Caterina 2007; Palazzo et al. 2012a ). This anatomical proximity appears critical for inflammatory and neuropathic pain development (Hu et al. 2002; Jin et al. 2009 ). The intrathecal administration of mGluR1/mGluR5-selective agonists facilitates nocifensive behavior in mice Hu et al. 2007) . Conversely, the blockade of group I mGluRs by intrathecally administered antagonists or antisense oligonucleotides reduces formalinevoked nocifensive behavior Noda et al. 2003) and complete Freund's adjuvant- (Fundytus et al. 2002) or capsaicin-induced (Soliman et al. 2005 ) thermal hyperalgesia and mechanical allodynia. The expression of mGluR5 is mainly intracellular (80%) in primary cultures of dorsal horn neurons of the spinal cords of rats, and the blockade of the intracellular expression reduces neuropathic pain symptoms and signaling, whereas the blockade of membrane mGluR5 has little effect (Vincent et al. 2016) .
At the supraspinal level, studies of the role of group I mGluRs in pain modulation have been conducted in the amygdala, PAG, thalamus, and prefrontal cortex. In the central nucleus of the amygdala (CeA), group I mGluR stimulation enhances the synaptic transmission of pain information. mGluR1, which is overexpressed in the CeA in arthritic pain conditions, contributes to plasticity in the CeA during pathological pain (Neugebauer et al. 2003; Li and Neugebauer 2004) . Patch-clamp recordings of rat slices containing the CeA have shown that the mGluR1 acts at the presynaptic level to increase excitatory transmission and decrease inhibitory transmission, whereas the mGluR5 acts at the postsynaptic level to facilitate both excitatory and inhibitory inputs (Ren and Neugebauer 2010) . Other studies have shown that stimulation of the group I mGluRs in the CeA mimics peripheral hypersensitivity that is induced by injury in mice, and this seems to be mediated by mGluR5 (Kolber et al. 2010) . In vitro and in vivo electrophysiological recordings have shown that mGluR1 is also involved in neuroplasticity in the basolateral amygdala-medial prefrontal cortex circuitry in chronic pain conditions, while mGluR5 is not Neugebauer 2010, 2011; Sun and Neugebauer 2011; Luongo et al. 2013) . In the ventrobasal thalamus, single-unit extracellular recordings in anesthetized rats have shown that activation of mGluR1 and mGluR5 potentiate neuronal responses to nociceptive stimuli, while their blockade reduces the neuronal responses (Salt and Binns 2000) . Conversely, group I mGluR stimulation in the PAG reduces behavioral responses to nociceptive stimuli, possibly as a result of the stimulation of PAG activity and the subsequent enhancement of the pain descending pathway. Group I mGluRs in the PAG appear to also be necessary for NMDA-, cannabinoid-, and vanilloidinduced antinociceptive effects (Maione et al. 1998 (Maione et al. , 2000 Berrino et al. 2001) . Indeed, intra-PAG microinjections of group I mGluR antagonists block antinociception that is induced by WIN55, 212-2, capsaicin, and NMDA in the plantar test Palazzo et al. 2001 Palazzo et al. , 2002 Palazzo et al. , 2012b de Novellis et al. 2005) .
Group II mGluRs are widely distributed along the pain neuraxis (Jia et al. 1999; Carlton et al. 2001; Tamaru et al. 2001) . The systemic administration of (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), (1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY379268), and (4S,6S)-4-amino-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY389795), group II mGluR agonists, reduced nocifensive responses in the second phase of the formalin model of persistent pain. In the L5/L6 spinal nerve ligation model of neuropathic pain in rats, LY379268 significantly reversed mechanical allodynia in a dose-related manner, but it had no significant effects on the tail flick test or paw withdrawal test of acute thermal nociceptive function (Simmons et al. 2002) . These results support the involvement of group II mGluR2,3 receptors in pathological pain only and suggest the potential utility of selective group II mGluR agonists for the treatment of persistent pain. The peripheral activation of group II mGluRs by the injection of selective agonists into animal hind paws inhibits nociceptive responses that are induced by carrageenan/prostaglandin E2 Gereau 2002, 2003) , bee venom (Chen et al. 2010) , interleukin-1beta (Jung et al. 2006) , and capsaicin (Carlton et al. 2009a,b) . Consistent with these findings, pain responses are also reduced after the peripheral administration of inhibitors of the enzyme that inactivates the peptide neurotransmitter N-acetylaspartylglutamate (NAAG), which is a selective agonist of group II mGluRs (Yamamoto et al. 2007 ). The intrathecal administration of group II mGluR agonists enhances pain responses in healthy (Fisher and Coderre 1996a; Zhou et al. 2011 ) and formalin-treated rats (Fisher and Coderre 1996b) while inhibiting sensory symptoms in neuropathic pain conditions (Fisher et al. 2002; Zhou et al. 2011) . However, the intrathecal administration of NAAG peptidase inhibitors suppresses pain responses induced by either formalin or partial sciatic nerve ligation in rats (Yamamoto et al. 2004) . In vitro studies of whole-cell voltage clamp recordings in spinal cord slices have shown that (2S,2 0 R,3 0 R)-2-(2 0 ,3 0 -dicarboxycyclopropyl)glycine (DCG-IV), a group II mGluR agonist, inhibits excitatory postsynaptic currents with enhanced potency in nerve-injured rats . Microinjections of NAAG and NAAG peptidase inhibitors into the lateral ventricle reduce formalin-induced nocifensive behaviors (Yamamoto et al. 2008) . In the PAG, group II mGluR stimulation either increases (Maione et al. 1998) or reduces (Maione et al. 2000; Yamada et al. 2012 ) behavioral responses to painful stimuli. In the thalamic reticular nucleus, local injections of (2S)-a-ethylglutamic acid (EGlu), a group II mGluR antagonist, inhibit pain responses in ankle-bend tests of nociception in monoarthritic rats, which suggests that group II mGluRs are pronociceptive in the thalamus, like they are in the spinal cord and PAG . In the CeA, the perfusion of LY354740 by reverse microdialysis inhibits neuronal responses to knee and ankle stimulation in anesthetized control and arthritic rats (Li and Neugebauer 2006) . Moreover, the application of a NAAG peptidase inhibitor or group II mGluR agonists in the laterocapsular division of the CeA attenuates evoked excitatory postsynaptic currents in formalin-induced inflammatory pain in mice (Adedoyin et al. 2010) . Recently, the antinociceptive effects of group II mGluR agonists have been reported to be primarily mediated by the activation of mGlu2R (Neale et al. 2011; Zammataro et al. 2011) . Moreover, the analgesic effects of L-acetylcysteine in models of inflammatory and neuropathic pain might result from the ability of L-acetylcysteine to increase mGluR2 expression (Bernabucci et al. 2012) . A contribution of mGluR3 to pain modulation was suggested by findings of the over-expression of mGluR3 in the spinal cord and cerebral cortex during chronic pain states (Boxall et al. 1998; Neto et al. 2001; Dolan et al. 2003) . Novel mGluR2-and mGluR3-selective PAMs and negative allosteric modulators (NAMs) have recently been developed (Sheffler et al. 2011) . Because these selective agents are not widely available to the scientific community, few studies have investigated their effects, especially in the context of pain. Overall, the role of group II mGluRs in pain control is far from clear: they proved ineffective (in healthy conditions), pronociceptive (intrathecal, -PAG, and -thalamus) or antinociceptive depending on the pain pathway area in which they are stimulated or the animal pain model is used. However, the importance of group II mGluRs in pain modulation is clear, and their efficacy in neuropathic and cancer pain models suggests the use of group II mGluR-targeting agents in bone cancer (Saito et al. 2006) and neuropathic pain therapies.
Group III mGluRs and pain
Peripheral group III mGluRs Other than mGluR6, which is expressed primarily in the retina (Vardi et al. 2000) , group III mGluRs are widely expressed within the peripheral and central nervous systems. In particular, mGluR4, mGluR7, and mGluR8 are expressed on the terminals of sensory afferent neurons (Ohishi et al. 1995; Carlton and Hargett 2007) , and mGluR4 and mGluR7 are found at the spinal level (Ohishi et al. 1995; Li et al. 1997; Azkue et al. 2001) . The broad-spectrum group III mGluR agonist, (S)-2-amino-4-phosphonobutanoate (L-AP4), does not alter thermal and mechanical thresholds when it is intraplantarly administered in healthy rats (Govea et al. 2012) . In contrast, intraplantar L-AP4 reduces pain responses induced by capsaicin (Carlton et al. 2011; Govea et al. 2012) , foskolin (Govea et al. 2012) , and bee venom (Chen et al. 2010) . Similarly, intraplantar injections of a-methyl-3-methyl-4-phosphonophenylglycine (MPPG), which is a group III mGluR antagonist, does not alter pain-related behavior in na€ ıve rats, while it reduces nociceptor electrical activity following capsaicin administration in intact skin-nerve preparations (Govea et al. 2012) . mGluR8 is co-expressed with TRPV1 on unmyelinated cutaneous axons. Group III mGluR stimulation and the subsequent inhibition of the cAMP/protein kinase A pathway (Prezeau et al. 1992; Schoepp and Johnson 1993; Tanabe et al. 1993; Pin and Duvoisin 1995) would inhibit TRPV1 activity, which would then silence pain (De Petrocellis et al. 2001; Bhave et al. 2002; Carlton et al. 2009a; Govea et al. 2012) . Increases in nociceptor stimulation by TRPV1 agonists and/or chronic pain conditions result in massive glutamate release, which diffuses to axon terminals expressing group III mGluRs, the activation of which prevents additional glutamate release (Kilbride et al. 1998; Anwyl 1999; Cartmell and Schoepp 2000; Gerber et al. 2000; Taverna and Pennartz 2003) . The contribution of group III mGluRs to the correction of extensive glutamatergic activation would result in pain perception normalization during chronic pain states. Indeed, even though the mechanisms differ from those of group II mGluRs, group III mGluRs negatively regulate glutamate release (Pin and Duvoisin 1995; Wroblewska et al. 2006) . Group III mGluRs also inhibit sodium channel activity, which consequently reduces primary afferent sensory transmission (Gerber et al. 2000; Thomas et al. 2001) . However, because the group II and group III mGluRs seem essential for maintaining proper nociceptor firing, they play a protective role in the central sensitization associated with chronic pain (Carlton et al. 1995 (Carlton et al. , 2009b Du et al. 2003 Du et al. , 2006 Brennan 2004, 2008; Shim et al. 2005; Ji et al. 2007 Ji et al. , 2008 . Peripheral-acting agonists that target group II and/or group III mGluRs may show therapeutic effectiveness in chronic pain states without central side effects.
Spinal group III mGluRs
Of the group III mGluRs, only mGluR4 and mGluR7 have been found on the afferent endings of primary sensory neurons in the superficial laminae of the spinal cord dorsal horn (Ohishi et al. 1995; Li et al. 1997) . L-AP4 inhibits excitatory responses in in vitro whole-cell recordings of lamina II neurons. This inhibition is greater in nerve-injured rats than in control rats (Zhang et al. 2009 ). Intrathecal injections of (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid (ACPT-1), which is a selective group III mGluR agonist, does not change vocalizations induced by mechanical or thermal stimuli in healthy subjects, whereas it inhibits nociceptive responses under inflammatory or neuropathic pain conditions in rats (Goudet et al. 2008) . Similar effects are observed following intrathecal injections of N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide (PHCCC) or (AE)-cis-2-(3,5-dichlorphenylcarbamoyl) cyclohexanecarboxylic acid (VU0155041), two novel mGluR4-selective PAMs that alleviate pain symptoms in neuropathic rats (Goudet et al. 2008; Wang et al. 2011) . It is noteworthy, however, that ACPT-1 is also a mGluR1 antagonist (Annoura et al. 1996; Maj et al. 2003) . The intrathecal administration of L-AP4 also alleviates capsaicininduced mechanical and thermal hypersensitivity and neuropathic pain symptoms (Fisher et al. 2002; Chen and Pan 2005; Soliman et al. 2005) . Altogether, these findings suggest that spinal group III mGluRs modulate pain in pathological states of various etiologies but not under normal conditions (Fisher and Coderre 1996a; Chen and Pan 2005) . However, (S)-2-methyl-2-amino-4-phosphonobutanoate (M-AP4), which is a group III mGluR antagonist, decreases paw withdrawal thresholds and increases the activity of ascending dorsal horn neurons in normal but not nerve-injured anesthetized rats (Chen and Pan 2005) . M-AP4 not only is a specific antagonist of group III mGluRs, but it also acts as a group II mGluR agonist. Thus, its efficacy in modulating pain in healthy conditions may be because of its hybrid pharmacological properties (Fisher and Coderre 1996a,b; Zhou et al. 2011) . The infusion of L-AP4 by reverse microdialysis into the dorsal horn of the spinal cord in monkeys inhibits the responses of spinothalamic tract neurons to peripheral mechanical stimuli in healthy conditions and reverts capsaicin-induced sensitization (Neugebauer et al. 2000) . While the effects on capsaicininduced sensitization are consistent with previous findings of an effect of group III mGluRs in inflammatory pain conditions, the effects of L-AP4 in the spinothalamic tract of primates under normal conditions differ from those seen in rodents (Chen and Pan 2005) , which thus suggests a possible species specificity of L-AP4. N,N 0 -dibenzyhydryl-ethane-1,2-diamine dihydrochloride (AMN082) was developed as a mGluR7-selective allosteric agonist that acts on transmembrane domains (Mitsukawa et al. 2005) . When intrathecally administered, AMN082 reduces the mechanical allodynia and thermal hyperalgesia that are induced in rats after injections of carrageenan into hind paws or hind paw incisions (Dolan et al. 2009 ). In addition, AMN082 relieves nocifensive responses and mechanical hyperalgesia after intradermal injections of formalin into the lower forelimbs of sheep (Dolan et al. 2011) . However, the intrathecal administration of AMN082 does not relieve hyperalgesia in neuropathic pain conditions in rats (Wang et al. 2011 ).
The effects of broad-spectrum ligands on supraspinal group III mGluRs PAG The effects of broad-spectrum agonists of group III mGluRs in the PAG are unclear because of the opposite effects that mGluR7/8 subtypes within the same group exhibit and the different affinity of each compound for the subtypes (see forward). Local microinjections of L-serine-O-phosphate (SOP) into the PAG reduce thermal thresholds in hot plate tests (Maione et al. 1998 ) and enhance nocifensive responses in the second phase of formalin tests in mice . The effects of L-SOP need to be evaluated with caution because it activates group III mGluRs and antagonizes group I and group II mGluRs (Antflick et al. 2009; Kang et al. 2014) . In addition, L-SOP decreases GABA release and increases extracellular serotonin and glutamate release in the PAG (Maione et al. 1998b; Marabese et al. 2005) . The stimulation of neurotransmitter release by group III mGluRs might be a consequence of the decrease in GABA because of their expression on GABAergic terminals. The presynaptic modulation of the release of these neurotransmitters within the PAG is critical for pain modulation because GABAergic interneurons tonically inhibit the PAG antinociceptive pathway (Moreau and Fields 1986) . Thus, group III mGluR agonists produce pain inhibition (as a result of decreased GABAergic tone and enhancement of the descending antinociceptive pathway). (RS)-a-methylserine-O-phosphate (M-SOP), which is a group III mGluR antagonist, blocks cannabinoid-induced analgesia and, when used alone, reduces thermal thresholds in healthy rats . Moreover, it reduces nocifensive behavior in the second phase of formalin tests . The effects of the group III mGluR antagonist, M-SOP, needs to be investigated further because these effects might depend on the different affinities of M-SOP for the different group III mGluR subtypes.
Thalamus
In the thalamus, L-AP4 depresses cortical input responses and reduces GABA inhibition in rats. These effects are reverted by M-AP4 and (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495), which are group II/III mGluRs antagonists, but not by EGlu, which is a group II mGluR antagonist. The potencies and selectivities of these compounds on mGluR4, mGluR7, and mGluR8 suggest that the depression of thalamocortical responses by L-AP4 occurs through mGluR7 and mGluR8 and not mGluR4 (Turner and Salt 1999) .
Amygdala
The stimulation of group III mGluRs in the CeA of healthy rats by L-AP4 inhibits neuronal responses in the laterocapsular division of the CeA (CeLC) to knee and ankle stimulation. This inhibition is enhanced under arthritis inflammatory pain conditions, which suggests that the CeLC neurons exhibit neuroplasticity under chronic pain conditions. Accordingly, a-methyl-3-methyl-4-phosphonophenylglycine (MPPG), which is a group III mGluR antagonist, facilitates the responses of CeLC neurons to knee and ankle stimulation under arthritic pain conditions, but it is ineffective in normal conditions (Li and Neugebauer 2006) .
The effects of subtype-specific ligands on supraspinal group III mGluRs
The selective targeting of group III mGluR subtypes is possible after the development of compounds that target the allosteric binding sites on mGluRs. The binding sites of PAMs and NAMs on the transmembrane domains are less conserved across the eight mGluR subtypes, which thus permits the synthesis of agents that are selective for each of the eight subtypes (Sheffler et al. 2011; Urwyler 2011; Flor and Acher 2012; Engers and Lindsley 2013; Conn et al. 2014; Walker and Conn 2015) . These allosteric modulators can increase or decrease mGluR activity like agonists and antagonists. However, mGluR PAMs and NAMs exhibit higher selectivity and have the advantage of modulating endogenous agonist activity without perturbing mGluR signaling in the absence of glutamate (Conn et al. 2014) . Theoretically, allosteric modulators can bypass problems, such as receptor desensitization and/or down-regulation and the possibility of acute toxicity from excessive doses. Their greater selectivity and potential advantages would permit their investigation as potential clinical candidates in the treatment of various brain disorders.
mGluR4
The only study that has investigated the role of mGluR4 was conducted at the supraspinal level in the dorsal striatum. Local injections of VU015504 into the dorsal striatum in sham and neuropathic rats failed to change the tail flick latency or activity of the ON and OFF cells of the rostral ventromedial medulla (RVM) (Rossi et al. 2014) . ON cells are excited by nociceptive stimuli and inhibited by centrally acting analgesics, whereas OFF cells are inhibited by noxious stimuli and activated by analgesics. Thus, ON and OFF cells are often exploited electrophysiologically in investigations of a compound's ability to modulate pain (Fig. 1) .
mGluR7
Group III mGluR agonists, such as L-AP4, L-SOP, and ACPT-1, display low affinity for the mGluR7 subtype and do not penetrate the blood-brain barrier. Thus, they are not suitable in investigations of the supraspinal role of this receptor subtype (Acher et al. 1997; Pin et al. 1999; Pałucha-Poniewiera et al. 2008) . LY341495, which is a competitive group III mGluR antagonist that displays high potency but little selectivity, is also a potent antagonist of group II mGluRs (Kingston et al. 1998) . The group III mGluR antagonists MSOP, (RS)-phosphonopentanoic acid (CPPG), and M-AP4 show selectivity but weak potency (Pin et al. 1999; Schoepp et al. 1999) . Thus, information on the role of mGluR7 at the supraspinal level comes from investigations using AMN082 (Mitsukawa et al. 2005) . Microinjections of AMN082 into the ventrolateral (VL) PAG stimulate the mGluR7 at this level, which facilitates nociception, which is the opposite of the effects of mGluR8-selective stimulation (see forward) (Marabese et al. 2007a, b) . In particular, intra-PAG microinjections of AMN082 dose-dependently decrease thermal thresholds in healthy rats (Marabese et al. 2007a,b) . This facilitatory effect on pain transmission is associated with consistent changes in ON and OFF cells and decreases in glutamate release into the VL PAG (Marabese et al. 2007b) , which suggests that mGluR7 stimulation at the PAG level causes descending pathway inhibition and pain facilitation (Heinricher and Tortorici 1994; Ferrante et al. 2009 ). The same facilitatory effects of AMN082 on pain have been found in the CeA (Palazzo et al. 2008) . Local perfusion of AMN082 into the CeA by reverse microdialysis decreases spinal withdrawal reflex thresholds, increases audible and ultrasonic vocalizations evoked by brief mechanical pressure of the knee, and enhances anxietylike behaviors in healthy rats. When tested in arthritic subjects, AMN082 fails to modulate spinal reflexes, vocalizations, or anxiety-like behavior, which suggests that mGluR7 may facilitate nocifensive behavior only under healthy conditions and not in chronic pain states (Palazzo et al. 2008) in which enhanced glutamatergic transmission leads to plastic changes in the CeA (Neugebauer et al. 2003; Bird et al. 2005; Ikeda et al. 2007) . The effects of the mGluR7 in the CeA are therefore the opposite of those of the other group III mGluRs, the modulation of which is effective only during chronic pain conditions. In the nucleus tractus solitarius (NTS), AMN082 inhibits cardiac-somatic reflexes induced by pericardial capsaicin in rats, which shows that the mGluR7 in the NTS inhibits pain transmission (Liu et al. 2012) , which is the opposite of its effects in the VL PAG and CeA. The evidence that both M-SOP and vagal deafferentation eliminate AMN082's inhibition of cardiac nociception strengthens the idea that the mGluR7 in the NTS inhibits pain. The mGluR7 stimulates glutamatergic presynaptic terminals by decreasing glutamate release, which then impairs nociceptive information transmission from the NTS to the spinal cord (Liu et al. 2012) . However, AMN082 has little selectivity in vivo because it is rapidly metabolized into an active compound that inhibits monoamine transporter activity (Sukoff Rizzo et al. 2011) . Moreover, because AMN082 induces rapid and long-lasting receptor internalization, it paradoxically behaves like a mGluR7 blocker (Pelkey et al. 2007 ). Thus, the recent discovery of novel NAMs of the mGluR7 has contributed to a better understanding of the functional role of mGluR7 at the supraspinal level. 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazolo[4,5-c]pyridin-4(5H)-one (MMPIP) was the first selective NAM of the mGluR7 that was developed. MMPIP, which also acts as an inverse agonist of mGluR7, exhibits good brain penetration after systemic administration (Suzuki et al. 2007; Hikichi et al. 2010) . When administered into the VL PAG, MMPIP shows no effects in healthy rats, but it inhibits pain responses in formalin and neuropathic pain models. The inhibition of pain thresholds by MMPIP is associated with consistent changes in RVM neuronal activity, which therefore suggests that MMPIP activates the antinociceptive descending pathway at the PAG-RVM circuitry level when it is administered into the VL PAG. Indeed, MMPIP increases the activity of antinociceptive OFF cells and decreases the activity of pronociceptive ON cells in neuropathic rats, which is consistent with antinociception, and MMPIP is ineffective in healthy controls (Palazzo et al. 2013) . Thus, this mGluR7 NAM seems to act the opposite of AMN082, which facilitates pain transmission only under normal conditions. Consistent with the efficacy of MMPIP in chronic pain models and its lack of effects in healthy animals, MMPIP shows context-dependent activity in recombinant cell lines and inactivity under normal physiological conditions Fig. 1 A simplified scheme of the effects of metabotropic glutamate receptor (mGluR) mGluR4 and mGluR7 stimulation (ON) or blockade (OFF) on pain responses in supraspinal areas. The facilitation of pain responses is indicated by ON, whereas inhibition is indicated by OFF. The condition (normal or chronic pain), brain area, and references are also given. . A summary of the effects of mGluR7 stimulation or blockade that have been found in supraspinal areas to date is given in Fig. 1. 
mGluR8
The current understanding of the role of mGluR8 in the regulation of pain transmission stems from the development of (S)-3,4-dicarboxyphenylglycine (DCPG), which is a mGluR8a receptor agonist (Thomas et al. 2001) . However, DCPG is only marginally selective for mGluR8 because high concentrations of DCPG also activate the mGluR2 (Mercier et al. 2013) . The effects of DCPG have been investigated so far in the amygdala, PAG, dorsal striatum, and NTS. In the CeA, DCPG perfusion by reverse microdialysis, which has no effects in normal animals, inhibits spinal reflex responses to noxious stimulation and audible and ultrasonic vocalizations of arthritic rats. In addition, DCPG increases the openarm choice, which suggests anxiolytic-like effects in arthritic pain conditions (Palazzo et al. 2008) . The analgesic effects of intra-CeA DCPG in only pathological conditions was confirmed in a subsequent study that showed that DCPG did not change the thermoceptive threshold, the activity of ON and OFF cells in the RVM, or serotonin, glutamate, or GABA release in healthy rats. Instead, DCPG produces antinociception, increases serotonin and glutamate, and decreases GABA in carrageenan-induced inflammatory pain. After carrageenan administration, ON cell activity has been found to be inhibited, while OFF cell activity has been enhanced, and increases have been observed in mGluR8 gene and protein staining, the latter being associated with vesicular GABA transporter-positive profiles. Thus, the over-expression of mGluR8 might be critical for DCPG effectiveness in inflammatory pain conditions (Palazzo et al. 2011) . The intra-VL PAG administration of DCPG increases tail flick latency and activates OFF cell activity in healthy subjects, which suggests that the plastic changes in the PAG that are induced by persistent pain are not critical for DCPG's pain inhibition. DCPG has also been shown to act as an analgesic in inflammatory and neuropathic pain models when it is either systemically or locally administered into the PAG in mice (Marabese et al. 2007b) . In particular, DCPG reverts formalin-induced nocifensive behavior and inhibits the development of carrageenan-or neuropathic pain-induced hyperalgesia and allodynia (Marabese et al. 2007a ). In addition, DCPG increases glutamate and decreases extracellular GABA concentrations in healthy rats. The glutamate increases and GABA decreases in the PAG would in turn activate the descending pain system and antinociceptive activity. This may be the source of DCPG's antinociceptive properties at the PAG level . A recent study showed that the local administration of DCPG into the dorsal striatum did not modify the mechanical withdrawal threshold and the activity of the ON and OFF cells in sham rats, but, in neuropathic rats, DCPG reverted mechanical allodynia and inhibited the ongoing and tail flick-evoked activity of ON cells, while increasing the activity of OFF cells (Rossi et al. 2014) . Changes in mGluR8 expression on GABAergic terminals in the dorsal striatum are found in neuropathic pain conditions. 2-[[(4-Bromophenyl)methyl] thio]-N-[4-(1-methylpropyl)phenyl]acetamide (AZ12216052), which is a selective mGluR8 PAM (Duvoisin et al. 2010) , behaves like DCPG when it is administered into the dorsal striatum. However, AZ12216052 is less potent for changing thermoceptive reactions and RVM cell activities compared with DCPG (Rossi et al. 2014) . In the NTS of rats, mGluR8 stimulation by DCPG increases the cardiac-somatic reflex that is induced by pericardial capsaicin, which shows that mGluR8 at the NTS level has facilitatory effects on cardiac nociception (Liu et al. 2012) . It is difficult to definitively determine the role of supraspinal mGluR8 in modulating pain transmission because its effects strictly depend on the cerebral site where it is stimulated and whether the conditions are normal or involve pathological pain. In summary, when delivered systemically or into the PAG, dorsal striatum, or CeA, the stimulation of the mGluR8 by DCPG reduces pain responses, while it facilitates nociception when administered into the NTS. A characteristic of this mGluR subtype is its plasticity-dependent analgesic role under chronic pain conditions in the CeA and dorsal striatum, but not in the PAG (see Palazzo et al. 2014a,b, for review) . The effects of mGluR8 stimulation in supraspinal brain sites are summarized in Fig. 2 .
The effects of systemic administration Only a few of the studies on the effects of group III mGluRs on pain modulation have investigated the effects of the systemic administration of agonists or antagonists. The systemic administration of DCPG relieves formalin-induced nocifensive behaviors, carrageenan-induced thermal hyperalgesia and mechanical allodynia, and the early stage of neuropathic pain (Marabese et al. 2007b) . The systemic administration of AMN082 inhibits thermal hyperalgesia and mechanical allodynia following incision or intradermal administration of carrageenan into the hind paw (Dolan et al. 2009 ). First, in vivo studies of MMPIP, a mGluR7 NAM, have shown that the negative allosteric modulation of the mGluR7 impairs cognitive performance in object recognition and radial arm maze tasks and reduces social interaction. MMPIP does not affect motor coordination, anxiety-and depression-like behaviors, sensorimotor gating, seizure threshold, or nociception in healthy mice and rats (Hikichi et al. 2010) . The systemic subcutaneous administration of MMPIP reverts the sensory and affective/cognitive symptoms of neuropathic pain in the spared nerve injury model of neuropathic pain, while it is ineffective in control mice. The changes in receptor expression in some supraspinal areas, such as the basolateral amygdala, dorsal raphe, prelimbic cortex, PAG, and hippocampus, that have been observed in neuropathic conditions may be necessary for enhancing MMPIP's effects (Palazzo et al. 2015) . Another selective mGluR7 NAM, which has been developed is the 7-hydroxy-3-(4-iodophenoxy)-4H-chromen-4-one (XAP044). XAP044 inhibits long-term potentiation in brain slices containing the lateral amygdala in wild-type mice but not in mGluR7 knockout mice, which suggests XAP044-specific actions on mGluR7 (Gee et al. 2014) . In vivo experiments have shown that XAP044 penetrates the brain and, like mGluR7 knockout mice phenotype, produces antistress-, antidepressant-, and anxiolytic-like effects and reduces freezing in a fear-conditioning paradigm (Gee et al. 2014) . A single subcutaneous administration of XAP044 reverts mechanical allodynia and ameliorates anxiety-and depression-like behaviors in neuropathic pain conditions in mice (Palazzo et al. 2015) . Interestingly, (+)-6-(2,4-dimethylphenyl)-2-ethyl-6,7-dihydrobenzo [d]oxazol-4(5H)-one (ADX71743), which is another selective mGluR7 NAM, has demonstrated excellent brain penetration and anxiolytic-like effects in the elevated plus maze and marble burying tests after subcutaneous administration in rats and mice. Furthermore, ADX71743 reduces amphetamine-induced hyperactivity without altering locomotor activity in normal conditions (Kalinichev et al. 2013) . The recent development of selective mGluR7 NAMs has profoundly contributed to the delineation of a functional role of mGluR7 in physiological and pathological pain conditions. Aside from providing a better understanding of mGluR7 functions at the synapse, MMPIP, XAP044, and ADX71743, but not AMN082, exhibit consistent results with the mGluR7 knockout mice phenotype (Cryan et al. 2003; Mitsukawa et al. 2006) . MMPIP and XAP044 are analgesic in chronic pain conditions, and they alleviate comorbid affective and cognitive disorders. Thus, their possible therapeutic exploitation is desirable.
Conclusions
The multidirectional effects of group III mGluR stimulation on pain responses depend first on the selectivity of the compounds on the particular mGluR subtype. Indeed, mGluR7 and mGluR8 have opposite roles on pain modulation. The varieties of the effects depend on the neuron type (glutamate or GABA) upon which the receptor is mainly located within the brain site. When given systemically, the total effects of the group III mGluR ligands depend on the compound hydrophilicity, which affects the receptor modulation at the peripheral, spinal, or supraspinal level. The novel subtype-selective allosteric modulators of group III mGluRs are able to penetrate the blood-brain barrier. mGluRs are widely expressed in the pain pathway, which makes it difficult to understand the mechanism and the site of action through which mGluR modulation takes place. Studies on the role of supraspinal group III mGluRs have performed local microinjections and/or perfusions of subtype-selective group III mGlu ligands and showed that mGluR7 antagonists and mGluR8 agonists exert analgesic activities in the PAG, dorsal striatum, and CeA, whereas in the NTS, they have the opposite effect. Moreover, these allosteric modulators modulate pain responses differently during physiological or pathological states. In particular, mGluR8 agonists inhibit pain only under pathological activation in the CeA and dorsal striatum and not in the PAG, where DCPG is also effective in normal conditions. The local administration of mGluR antagonists, such as MMPIP, into the PAG alleviates pain responses in chronic pain but has not effects in healthy conditions. Thus, these antagonists behave like group II mGluRs and opiates. Although we are still far from a deep understanding of the role of each group III mGluR subtype in the processing of noxious information within supraspinal sites, the potential for silencing pain by targeting mGluRs appears unlimited. Selective mGluR subtype allosteric modulators are attractive candidates for analgesics. mGluR7 NAMs and mGluR8 PAMs can modulate glutamate transmission when it is altered, such as in pathological pain states.
